World’s First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rongyu's world's first independently developed serum-free iterative rabies vaccine has successfully passed the National Medical Products Administration...
VARON Marks Valentine’s Day With Health-Focused Savings That Put Care First
Love looks like care. This Valentine's Day, VARON invites families to show love in a way that helps loved ones breathe easier—at home and on the go. NEW YORK, Feb. 6, 2026 /PRNewswire/ -- VARON, a trusted provider of respiratory care solutions, today announced its Valentine's Day Sale, a limited-time event designed to...
This Valentine’s Day, VARON Encourages Filipinos to Show Love Through Better Respiratory Health
MANILA, Philippines, Feb. 5, 2026 /PRNewswire/ -- Valentine's Day is traditionally associated with flowers and chocolates, but health experts encourage Filipinos to also prioritize well-being for themselves and their loved ones. Respiratory health is increasingly important as more people manage chronic conditions, recover from illness, or maintain active lifestyles amid environmental challenges. VARON...
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field...
Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combining the innovative waste anaesthesia gas capture, collection, and processing...
Sore Back After Pre-New Year Cleaning? Herbalgy’s “Wellness Declutter” Method Shares 3 Tips to Sweep Away Pain for a Light, Energetic New Year
HONG KONG, Feb. 5, 2026 /PRNewswire/ -- As Lunar New Year approaches, many households dive into their annual deep cleaning, hoping to start the year in a fresh, orderly environment. However, intensive cleaning in a short period—repeated bending, squatting, kneeling, or lifting, can quickly lead to stiff shoulders, sore backs, and...
LifeZoom Introduces the Oclux Red Light Eye Mask–A Naturally Restorative, Aesthetics-Driven Solution for the Effects of Screen-Based Life
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- LifeZoom, a natural-restorative brand, today launches Oclux, a red light eye mask that expands the company's red light product lineup. Positioned as a holistic solution that balances visual aesthetics, user experience, and daily rhythms, Oclux is designed to help relieve the physical and mental imbalances associated with modern lifestyles and to guide...
Jin Medical CEO Fireside Chat
CHANGZHOU, China, Feb. 5, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat on February 2, 2026 where the CEO shared some insights into the Company's recent strategic priorities and long-term growth considerations. The following questions were prepared by...
Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors
Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts. CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors, is...
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike ISM8969, Insilico's brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency. Empowered by AI,...
